191 related articles for article (PubMed ID: 21303616)
1. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles.
Park JO; Stephen Z; Sun C; Veiseh O; Kievit FM; Fang C; Leung M; Mok H; Zhang M
Mol Imaging; 2011 Feb; 10(1):69-77. PubMed ID: 21303616
[TBL] [Abstract][Full Text] [Related]
2. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
[TBL] [Abstract][Full Text] [Related]
3. Development and
Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
[TBL] [Abstract][Full Text] [Related]
4. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
[TBL] [Abstract][Full Text] [Related]
5. Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma.
Li YW; Chen ZG; Zhao ZS; Li HL; Wang JC; Zhang ZM
World J Gastroenterol; 2015 Apr; 21(14):4275-83. PubMed ID: 25892879
[TBL] [Abstract][Full Text] [Related]
6. Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments.
Li W; Xiao X; Li X; Xu Y; Ma L; Guo L; Yan C; Wu Y
Contrast Media Mol Imaging; 2018; 2018():9169072. PubMed ID: 30275801
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3-Targeted
Labadie KP; Hamlin DK; Kenoyer A; Daniel SK; Utria AF; Ludwig AD; Kenerson HL; Li L; Sham JG; Chen DL; Orozco JJ; Yeung RS; Orvig C; Li Y; Wilbur DS; Park JO
J Nucl Med; 2022 Jul; 63(7):1033-1038. PubMed ID: 34772791
[TBL] [Abstract][Full Text] [Related]
8. Glypican-3 targeted delivery of
Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
[TBL] [Abstract][Full Text] [Related]
9. A GPC3-specific aptamer-mediated magnetic resonance probe for hepatocellular carcinoma.
Zhao M; Liu Z; Dong L; Zhou H; Yang S; Wu W; Lin J
Int J Nanomedicine; 2018; 13():4433-4443. PubMed ID: 30122918
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
11. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
[TBL] [Abstract][Full Text] [Related]
12. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Wang K; Kievit FM; Sham JG; Jeon M; Stephen ZR; Bakthavatsalam A; Park JO; Zhang M
Small; 2016 Jan; 12(4):477-87. PubMed ID: 26641029
[TBL] [Abstract][Full Text] [Related]
13. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
14. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies.
Mossenta M; Busato D; Dal Bo M; Macor P; Toffoli G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077433
[TBL] [Abstract][Full Text] [Related]
15. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
17. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of reduced graphene oxide nanosheets using multifunctional ultrasound nanobubbles for visualization and enhanced photothermal therapy.
Liu Z; Zhang J; Tian Y; Zhang L; Han X; Wang Q; Cheng W
Int J Nanomedicine; 2018; 13():7859-7872. PubMed ID: 30538464
[TBL] [Abstract][Full Text] [Related]
19. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
